Program
navlimetostat
Also written as “Navlimetostat”, “BMS-986504” and “[14C]Navlimetostat”.
Its studies are mostly in Lung Neoplasms · Brain Neoplasms · Carcinoma, Non-Small-Cell Lung · Mesothelioma · Pancreatic Neoplasms, led by Bristol-Myers Squibb.
Furthest: phase 3, since Jul 3, 202510 company-led studies, 10 open or runningNext primary completion: Dec 5, 2026 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bristol-Myers Squibb | 1010 open or running | phase 3since Jul 3, 2025 | Feb 1, 2022 | Dec 5, 2026phase 1 · NCT07777133 |
- Named in Bristol-Myers Squibb’s own pipeline as
navlimetostat
, phase 2, as of Oct 29, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 1, 2022First study: phase 1 study in MesotheliomaFirst studyNCT05245500 · 336 planned · United States
- Nov 1, 2024Phase 1 study in Advanced Solid Tumors With Homozygous MTAP DeletionNCT06672523 · 8 planned · Hungary, Spain
- Feb 27, 2025Phase 2 study in Carcinoma, Non-Small-Cell LungNCT06855771 · 182 planned · United States, Australia, China and more
- Jul 3, 20252 phase 3 studiesNCT07063745, NCT07076121
- Jul 21, 2025Phase 1 study in Advanced Solid TumorsNCT07077434 · 32 planned · China, Japan
- Mar 20, 2026Phase 2 study in Brain NeoplasmsNCT07492680 · 254 planned · United States, Belgium, Canada and more
- Apr 16, 2026Phase 1 study in Healthy ParticipantsNCT07544628 · 64 planned · United States
- Aug 18, 20262 phase 1 studiesNCT07777133, NCT07800897
Ahead
- Nov 2, 2026Primary completion: phase 1 study in Healthy ParticipantsNCT07544628
- Dec 5, 2026Primary completion: phase 1 study in Healthy Female ParticipantsNCT07777133
- Jan 19, 2027Primary completion: phase 1 study in Advanced Solid TumorsNCT07077434
- Mar 25, 2027Primary completion: phase 1 study in Healthy Female AdultsNCT07800897
TargetBeta
“An orally bioavailable methylthioadenosine (MTA)-selective inhibitor of the protein arginine methyltransferase 5 (PRMT5), with potential antineoplastic activity. Upon oral administration, PRMT5 inhibitor BMS-986504 targets, binds to and inhibits PRMT5 that is bound to MTA, a complex that is eleva…”NCIt, read by Claude
“An orally bioavailable methylthioadenosine (MTA)-selective inhibitor of the protein arginine methyltransferase 5 (PRMT5), ”NCIt, by rule
Other programs on PRMT5
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| PRMT5 Inhibitor AZD3470 | AstraZeneca | phase 2 | 2 |
| JBI-778rule | jubilant-therapeutics-india-limited | phase 2 | 2 |
| PRMT5 Inhibitor TNG456rule | tango-therapeutics-inc | phase 2 | 1 |
| PRMT5 Inhibitor BAY 3713372rule | Bayer | phase 2 | 1 |
| onametostatrule | Johnson & Johnson | phase 1 | 2 |
| PRMT5 Inhibitor SH3765rule | Nanjing Sanhome Pharmaceutical | phase 1 | 2 |
| PRMT5 Inhibitor BGB-58067rule | BeOne Medicines | phase 1 | 2 |
| PRMT5 Inhibitor IDE892rule | ideaya-biosciences | phase 1 | 1 |
| PEP08rule | pharmaengine | phase 1 | 1 |
Studies
All 10 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07800897Healthy Female Adults · Canada | 1 | Recruiting | Mar 25, 2027 | 80 |
| NCT07777133Healthy Female Participants · United States, Netherlands | 1 | Recruiting | Dec 5, 2026 | 6 |
| NCT07544628Healthy Participants · United States | 1 | Recruiting | Nov 2, 2026 | 64 |
| NCT07492680Brain Neoplasms · United States, Belgium, Canada and more | 2 | Recruiting | Aug 15, 2028 | 254 |
| NCT07077434Advanced Solid Tumors · China, Japan | 1 | Recruiting | Jan 19, 2027 | 32 |
| NCT07076121Pancreatic Neoplasms · United States, Argentina, Australia and more | 3 | Active, not recruiting | May 3, 2029 | 470 |
| NCT07063745Lung Neoplasms · United States, Argentina, Australia and more | 3 | Recruiting | Aug 12, 2031 | 590 |
| NCT06855771Carcinoma, Non-Small-Cell Lung · United States, Australia, China and more | 2 | Recruiting | Dec 29, 2028 | 182 |
| NCT06672523Advanced Solid Tumors With Homozygous MTAP Deletion · Hungary, Spain | 1 | Recruiting | Oct 25, 2027 | 8 |
| NCT05245500Mesothelioma · United States | 1 | Recruiting | Dec 10, 2027 | 336 |
How it is read
Names in the registry
- “Navlimetostat”, 5 entries
- “BMS-986504”, 4 entries
- “[14C]Navlimetostat”, 1 entry
- “MRTX1719”, 1 entry
Conditions, from the studies’ own filings
- Lung Neoplasms, 1 study
- Brain Neoplasms, 1 study
- Carcinoma, Non-Small-Cell Lung, 1 study
- Mesothelioma, 1 study
- Pancreatic Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.